TY - JOUR
T1 - β-blockers
T2 - A new role in cancer chemotherapy?
AU - Nagaraja, Archana S.
AU - Sadaoui, Nouara C.
AU - Lutgendorf, Susan K.
AU - Ramondetta, Lois M.
AU - Sood, Anil K.
N1 - Funding Information:
Portions of work in this paper were supported by NIH grants (CA140933, CA104825, CA109298, P50CA083639, P50CA098258, CA128797, U54CA151668, U54CA96300 and U54CA96297), Ovarian Cancer Research Fund Program Project Development Grant, Department of Defence (OC073399, W81XWH-10-1-0158, OC100237), the Zarrow Foundation, the Betty Ann Asche Murray Distinguished Professorship, the RGK Foundation, the Gilder Foundation, the estate of CG Johnson Jr and the Blanton-Davis Ovarian Cancer Research Program.
PY - 2013/11
Y1 - 2013/11
N2 - β-blockers are a class of drugs that are widely used in treating cardiac, respiratory and other ailments. They act by blocking β-adrenergic receptor-mediated signaling. Studies in various cancers have shown that patients taking a β-blocker have higher survival and lower recurrence and metastasis rates. This is supported by several preclinical and in vitro studies showing that adrenergic activation modulates apoptosis, promotes angiogenesis and other cancer hallmarks, and these effects can be abrogated by β-blockers. These studies provide a rationale for the use of β-blockers as adjuvants with cancer chemotherapy. However, all published studies so far are retrospective and most do not take into account the specific β-blocker used or address which is most likely to benefit cancer patients. The published epidemiological studies are correlative and have not examined the adrenergic receptor status of the tumors. Knowledge of the β-adrenergic receptor status of tumor cells is essential in choosing the best β-blocker for adjuvant therapy. A comprehensive, prospective study is necessary to definitively prove the utility of using β-blockers with chemotherapy and to identify the specific β-blocker most likely to benefit patients with cancer.
AB - β-blockers are a class of drugs that are widely used in treating cardiac, respiratory and other ailments. They act by blocking β-adrenergic receptor-mediated signaling. Studies in various cancers have shown that patients taking a β-blocker have higher survival and lower recurrence and metastasis rates. This is supported by several preclinical and in vitro studies showing that adrenergic activation modulates apoptosis, promotes angiogenesis and other cancer hallmarks, and these effects can be abrogated by β-blockers. These studies provide a rationale for the use of β-blockers as adjuvants with cancer chemotherapy. However, all published studies so far are retrospective and most do not take into account the specific β-blocker used or address which is most likely to benefit cancer patients. The published epidemiological studies are correlative and have not examined the adrenergic receptor status of the tumors. Knowledge of the β-adrenergic receptor status of tumor cells is essential in choosing the best β-blocker for adjuvant therapy. A comprehensive, prospective study is necessary to definitively prove the utility of using β-blockers with chemotherapy and to identify the specific β-blocker most likely to benefit patients with cancer.
KW - Catecholamines
KW - β-adrenergic receptor
KW - β-blockers
UR - http://www.scopus.com/inward/record.url?scp=84885780718&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84885780718&partnerID=8YFLogxK
U2 - 10.1517/13543784.2013.825250
DO - 10.1517/13543784.2013.825250
M3 - Review article
C2 - 23919278
AN - SCOPUS:84885780718
SN - 1354-3784
VL - 22
SP - 1359
EP - 1363
JO - Expert Opinion on Investigational Drugs
JF - Expert Opinion on Investigational Drugs
IS - 11
ER -